The lead time required for development of population pharmacokinetic (PK) and pharmacodynamic (PD) models places enormous pressure on data programming to expedite the transformation of disparate data into an analysis-ready dataset. Only then can modeling and simulation efforts be initiated as quickly as possible. The creation of the analysis-ready dataset is complicated by the complexity of the modeling to be performed. These datasets typically require pooling disparate data from multiple studies, including PK information, the drug dosing history, patient demography, laboratory data, concomitant medicines, and measures of efficacy and safety to create a time-ordered sequence of relevant events for each patient from the time of enrollment in a trial until its conclusion.